Phase 2 N=67 Gemcitabine Plus Albumin-bound Paclitaxel In Patients With Advanced Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Primary: Number of Participants With Dose-limiting Toxicities — 4; 0; 1 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=24 Restasis for Treatment of Brittle Nails
Brittle Nails
Primary: Change From Baseline in the Physician's Global Assessment (PGA) of Target Fingernails #1 and #2 — -1.4; -1.4 scores on a scale
Phase 2 N=24 Comparison of Retinol 1.0% and Tretinoin 0.02% in the Treatment of Moderate to Severe Photodamage and Wrinkles
Photodamaged Skin · Wrinkles
Primary: Global Photodamage Severity — 4.8; 5.45 units on a scale
Phase 2 N=28 Pharmacokinetics and Pharacodynamics of GW642444 in Paedetric Subjects
Asthma
Primary: Number of Participants With Any Adverse Event (AE) or Any Serious Adverse Event (SAE) During the Treatment Period — 6; 9; 0; 0 Participants
Phase 2 N=144 A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
Melanoma
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) - Phase 1 — 0; 0; 0; 0 Participants
Phase 2 N=622 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Moderate-Dose ICS Therapy.
Asthma
Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — -0.043; 0.232; 0.229; 0.221 Liters — p=<0.001
Phase 2 N=598 A Randomized Study To Evaluate The Efficacy And Safety Of An Investigational Drug In Adolescent And Adult Subjects With Asthma Uncontrolled on Non-steroidal Therapy.
Asthma
Primary: Mean Change From Baseline in Trough (Evening Pre-dose and Pre- Rescue Bronchodilator) FEV1 at Week 8 — 0.137; 0.239; 0.266; 0.341 Liters — p=0.095
Phase 2 N=20 Simvastatin (Zocor) Therapy in Sickle Cell Disease
Sickle Cell Disease
Primary: Change in Total Cholesterol Level — -16; -18; -18 mg/dL
Phase 2 N=60 A Study To Assess Single Dosage Strength Of GW685698/GW642444 Chronic Obstructive Pulmonary Disease (COPD)
Pulmonary Disease, Chronic Obstructive
Primary: Change From Baseline in Weighted Mean Heart Rate 0-4 Hours Post-dose at the End of the 28-day Treatment Period — -5.7; -5.1 Beats per minute (bpm)
Phase 2 N=37 An Efficacy and Safety Study of Decitabine in Participants With Myelodysplastic Syndrome (MDS)
Myelodysplastic Syndrome
Primary: Percentage of Participants With Response — 23.5 Percentage of Participants
Phase 2 N=81 Study of E7389 for Advanced or Metastatic Breast Cancer
Breast Cancer
Primary: Number of Subjects With Adverse Events. — 81 Participants
Phase 2 N=47 An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
Prostate Neoplasms
Primary: Percentage of Participants With Confirmed Prostate Specific Antigen (PSA) Response at Week 12 — 36.2 percentage of participants
Phase 2 N=4 Enhancing Attention in Adults With Compulsive Hoarding
Hoarding Disorder
Primary: Number of Patients Who Met and Exceeded Response Criteria of Attention Deficit Hyperactivity Disorder Symptom Scale — 4 participants
Phase 2 N=296 Effect of CPP-ACP Paste on Dental Caries in Primary Teeth
Dental Caries
Primary: the Mean Number of Enamel Carious Lesion — 13.69; 14.55 Surfaces
Phase 2 N=13 Safety and Efficacy Study of Isolagen TherapyTM in Treatment of Interdental Papillary Insufficiency
Interdental Papillary Insufficiency
Primary: Number of Responders Based on the Average Investigator Evaluation of Change From Baseline for All Treated Areas on the Global Ordinal Rating Scale (GORS) — 10 participants